March 4, 2024

Expiration of Marketing Alliance Agreement
for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets
Mitsubishi

TanabePharma

Corporation(HeadOffice:Chuo-ku,Osaka;

Representative Director: Akihiro Tsujimura; hereinafter, "Mitsubishi Tanabe Pharma")
and Daiichi Sankyo Company, Limited (Head Office: Chuo-ku, Tokyo; Representative
Director, President: Hiroyuki Okuzawa; hereinafter, "Daiichi Sankyo") will expire themarketing alliance agreement for the selective DPP-4 inhibitor, “TENELIA® Tablets”
and “TENELIA® OD Tablets” (both hereinafter, “TENELIA® Tablets/OD Tablets;”
generic name: Teneligliptin Hydrobromide Hydrate), and the SGLT2 inhibitor,“CANAGLU® Tablets” (generic name: Canagliflozin Hydrate), on September 2, 2024,
due to the expiration of the agreement.
Under the agreement, the distribution of TENELIA® Tablets/OD Tablets has been
conducted by Daiichi Sankyo, whereas the distribution of CANAGLU® Tablets has
been carried out by Mitsubishi Tanabe Pharma. Both companies have been jointly
engaged in information provision of the products. With the expiration of themarketing alliance agreement, Daiichi Sankyo will transfer the distribution rights ofTENELIA® Tablets/OD Tablets to Mitsubishi Tanabe Pharma and will end theinformation provision activities to medical institutions for all products, which are
currently jointly conducted with Mitsubishi Tanabe Pharma.
Mitsubishi Tanabe Pharma and Daiichi Sankyo will cooperate to ensure the smoothtransfer of the products, and from September 3, 2024, Mitsubishi Tanabe Pharma will
independently carry out the marketing and information provision activities forTENELIA® Tablets/OD Tablets and CANAGLU® Tablets.
Daiichi Sankyo will continue to market CANALIA® Combination Tablets (combinedTENELIA® and CANAGLU®) and both companies will continue to jointly engage in its
co-promotion.
Through a stable supply of ethical drugs and prompt and appropriate information
provision activities, Mitsubishi Tanabe Pharma and Daiichi Sankyo will continue
contributing to the prevention and treatment of diseases and people's health in Japan.

1Products:
TENELIA® Tablets 20 mg
TENELIA® Tablets 40 mg
TENELIA® OD Tablets 20 mg
TENELIA® OD Tablets 40 mg
CANAGLU® Tablets 100 mg◆Contact information
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group,
Corporate Communications Div., Osaka Corporate Communications Dept.)+81₋6-6205-5119
Daiichi Sankyo Co., Ltd.
Corporate Communications Department+81₋3-6225-1126◆About Mitsubishi Tanabe Pharma Corporation
Founded in 1678, Mitsubishi Tanabe Pharma, the pharmaceutical division of
Mitsubishi Chemical Group (MCG), is one of the oldest established pharmaceuticalcompanies, centering on the prescription drug business. In its management policy"Forging the future," MCG has positioned healthcare as one of its most important
strategic markets. Our company's MISSION is "A desired option for all who face theirillness." To achieve this, we will focus on oncology, in addition to central nervous
system, immuno-inflammatory diseases, and diabetes and renal diseases. In addition
to Precision Medicine, which identifies a patient population with high efficacy andsafety and provides a high level of satisfaction with treatment, we will also develop"around pill solutions" to address patient concerns, starting with treatment drugs,
with a focus on prevention, pre-existing diseases, prevention of disease progression,and prognosis.
https://www.mt-pharma.co.jp/◆About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to thesustainable development of society that discovers, develops and delivers newstandards of care to enrich the quality of life around the world. With more than 120
years of experience, Daiichi Sankyo leverages its world-class science and technology
to create new modalities and innovative medicines for people with cancer,
cardiovascular and other diseases with high unmet medical need. For more information,please visit www.daiichisankyo.com.

2